{"analyses":[{"ciLowerLimit":"0.701","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.057","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1509","pValueComment":"2-sided p-value","paramType":"Hazard Ratio (HR)","paramValue":"0.86","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.5","upperLimit":"51.7","value":"43.2"},{"groupId":"OG001","lowerLimit":"29.8","upperLimit":"44.2","value":"36.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"290"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.","id":"OG000","title":"Avelumab + Axitinib"},{"description":"Participants with aRCC received sunitinib 50 mg orally, QD on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2 in 6-week cycles). Each treatment cycle was of 42 days.","id":"OG001","title":"Sunitinib"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants who are randomized. Analysis was performed on subset of randomized participants, who were PD-L1 positive.","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of death due to any cause or censoring date, whichever occurred first (maximum up to approximately 89 months)","title":"Overall Survival (OS) in PD-L1 Positive Participants","type":"PRIMARY","unitOfMeasure":"Months"}